LI Xia, SHENASHEN Mohamed A, MEKAWY Moataz, TANIGUCHI Akiyoshi, EI-SAFTY Sherif A,3

Aluminum Hydroxide Nanosheets with Structure-dependent Storage and Transportation toward Cancer Chemotherapy

LI Xia1, SHENASHEN Mohamed A1, MEKAWY Moataz1, TANIGUCHI Akiyoshi2,3, EI-SAFTY Sherif A1,3

(1. Research Center for Functional Materials, National Institute for Materials Science, Ibaraki 305-0047, Japan; 2. Cellular Functional Nanomaterials Group, Research Center for Functional Materials, National Institute for Materials Science, Ibaraki 305-0044, Japan; 3. Engineering and Advanced Manufacturing, University of Sunderland, Sunderland, United Kingdom)

Alum has an excellent safety record and is the only licensed inorganic adjuvant for human vaccines. However, the exploration of alum nanosheets as chemotherapy drug delivery system, especially the clarification about the relationship between structures and drug loading properties, is totally insufficient. Herein, aluminum hydroxides (AlOOH) nanosheets with tunable specific surface area and pore size were synthesized by adjusting the synthesis time in the presence of triblock copolymers. The obtained materials exhibited the highest surface area about 470 m2/g. The structure-dependent chemotherapy drug loading capability for AlOOH nanosheets was observed: the higher specific surface area and pore size are, the higher amount of chemotherapy drug is loaded. AlOOH nanosheets loaded with doxorubicin showed a pH-dependent sustained release behavior with quick release in low pH about 5 and slow release in pH around 7.4. Doxorubicin-loaded AlOOH nanosheets exhibited much higher cancer cellular uptake efficiency than that in free form by flow cytometry. Moreover, doxorubicin-loaded AlOOH nanosheets with high specific surface area showed an increased cellular uptake efficiency and enhanced ratios of apoptosis and necrosis, compared with those showing low specific surface area. Therefore, AlOOH nanosheets are promising materials as chemotherapy drug delivery system.

aluminum hydroxide; nanosheet; cancer chemotherapy; storage; drug delivery

The World Health Organization reported that approximately 8.2 million people worldwide die from cancer annually, accounting for an estimated 13% of all deaths. Chemotherapy is a major type of cancer treatment that involves the use of cytotoxic chemotherapeutic agents to treat cancer cells that divide rapidly. However, chemotherapy through systematic administration suffers from severe side effects on normal tissues[1]and from multiple drug resistance (MDR)[2-3], which is responsible for the active expulsion of chemotherapy drugs from tumor cells and the survival of tumor cells treated with the drugs; the mechanism underlying this phenomenon involves the overexpression of P-glycoprotein, MDR- associated protein, and so on. Nanocarriers that encapsulate toxic drugs can minimize damage to normal organs and decrease the MDR of cancer cells[4-6]. An ideal drug carrier should possess excellent safety properties, accommodate large amounts of drug molecules, diffuse effectively through cancer cells, display controlled release behavior, and so on.

Two-dimensional (2D) nanosheets (NSs), such as graphene, silicate, transition metal dichalcogenides, and transition metal oxides have attracted tremendous interest as a newly emerging class of nanomaterials in drug delivery systems. These NSs possess a unique planar topography, ultrathin thickness, high degree of anisotropy, high surface-area-to-mass ratio, and the ability to adsorb large amounts of drug molecules[7-9]. Thus far, no study has reported the synthesis of aluminum hydroxide NSs with a tailored surface area and explored their use as chemotherapy drug carriers. Alum in the form of aluminum hydroxide, aluminum phosphate, or aluminum sulfate has been used in human vaccines for nearly a hundred years because of its lack of side effects; however, its mechanism remains unclear[10-13]. Alum is the only licensed inorganic adjuvant for human use by the Food and Drug Administration of the United States[10-12]. To date, few reports focused on tuning the shape, crystallinity, and surface reactivity of alum and on its effects on the biological system (such as the triggering NLRP3 inflammasome activation in THP-1 cells and murine bone marrow-derived dendritic cells)[14]. Precise control over aluminum hydroxide (AlOOH) NSs with tailored structures may exert a distinct influence on the accessibility of drug molecules, the interaction between drug molecules and the carriers, and the biological responses. Previous findings indicate that AlOOH NSs may serve as promising inorganic carriers with the lowest barrier for clinical transfer, but still need clarification about the relationship between structures and drug loading properties.

The present study reports a simple one-pot fabrication of AlOOH NSs with a tunable surface area and pore size by using P123 templates (scheme 1). Then, we establish the correlation between the nanostructure and chemotherapy drug loading capability of the NSs. To the best of our knowledge, this study is the first to report the effects of surface area and pore size of AlOOH NSs on chemotherapy drug delivery properties. Moreover, the cellular uptake and cancer cell viability of AlOOH NSs loaded with doxorubicin (Dox) were studied using DU145 prostate cancer cells. The NSs also showed good biocompatibility

1 Experimental

1.1 Synthesis of aluminum oxyhydroxide nanosheets

Aluminum oxyhydroxide nanosheets were synthesized by using the inorganic aluminum salt AlCl3as Al source, urea and triblock copolymer P123 as templates. In a typical synthesis, 0.00016 mol P123 and 0.01 mol AlCl3·6H2O were mixed in 20 mL water and aged in a shaking bath at 40 ℃ for 1. Then, 0.04 mol urea was added to the above sol solution, which was hydrothermally treated at 100 ℃ for 6.5 and 24 h, respectively. The final products were collected by centrifugation, extracted in ethanol for 1 d to remove the templates, washed with water and ethanol for 3 times, and named Al-L and Al-H, respectively.

1.2 Characterization

The morphology and structure of the nanosheets were observed under a JEM-2100 transmission electron microscope. Wide-angle powder X-ray diffraction (XRD) patterns were obtained using an 18 kW diffractometer (Bruker D8 Advance) with monochromated Cu Kα radiation. Zeta potential was analyzed using a zeta potential and particle size analyzer (ELSZ-1000, Photal, Otsuka Electronics) in an appropriate buffer. An ultraviolet– visible–near infrared spectrophotometer (SolidSpec-3700, Shimadzu) was used to record the Dox concentration before and after loading. The release curve of Dox from the materials was measured using a microplate reader with absorbance at 490 nm. The nitrogen adsorption– desorption isotherms were recorded on a BELSORP36 analyzer at 77 K under a continuous adsorption condition. Brunauer–Emmett–Teller and Barrett–Joyner–Halenda analyses were conducted to determine the surface area, pore size, and pore volume.

1.3 Drug loading and release

A 100 μg portion Al-L or Al-H mesoporous materials in 500 μL phosphate-buffered saline (PBS) solution (pH 8.0) and 50 μL Dox solution at 1 mg/mL in water were mixed and shaken at 100 r/min overnight at room temperature. Then, the mixture was centrifuged and washed once to obtain the final Al-L/Dox or Al-H/Dox complexes.

1.4 Apoptosis/necrosis assay and cellular uptake assay by flow cytometry

DU145 prostate cancerous cells with a density of approximately 4×104cells/cm2were cultured in 35 mm dishes containing RPMI1640 medium supplemented with 10% fetal bovine serum at 37 ℃ in humidified air containing 5% CO2overnight. Al-L or Al-H suspensions loaded with Dox were added into the above dishes at a final concentration of 5 and 25 μg/mL, respectively. Free Dox at an equivalent amount as that released from Al-H/Dox after 1 d at pH 5 were used as contrast. After 3 h of incubation, the cellular uptake efficiency of Dox was recorded with a flow cytometry analyzer (ICyt EC800). Moreover, after 1 d of incubation, apoptotic and necrotic cells were double-stained with Annexin V-FITC and propidium iodide (PI), and recorded by using the flow cytometry analyzer.

Scheme 1 Formation of AlOOH NSs, loading of chemotherapy drugs onto NSs, and intravenous injection of the as-prepared NSs

1.5 Direct observation of cellular uptake by confocal laser scanning microscope

For investigating the cellular uptake of Al-H/Dox complexes, fluorescein isothiocyanate (FITC) was conjugated with Al-H with the aid of 3-aminopropyltri-ethoxysilane to obtain FITC-Al-H samples. Then, Dox was loaded onto the FITC-Al-H samples under the same conditions mentioned above. DU145 cancer cells were seeded in a 35 mm glass bottom Petri dish at a density of 4×104cells/cm2. After incubation of cells overnight, FITC-Al-H/Dox complexes were added in the dish at a final concentration of 25 μg/mL. After 0.5, 2.5 and 24 h of incubation, the cells were washed twice with PBS and fixed with 4% paraformaldehyde for 20 min. Afterward, the cell nucleus was stained with Hoechst. The cellular uptake of the complexes was visualized under a confocal laser scanning microscope (CLSM, SP5, Leica).

1.6 In vivo safety test

To examine thesafety, C57/BL6 mice were administered intravenouslytail vein injection of Al-H (50 μg in PEG/saline), and acute toxicology, such as blood biochemistry, was measured after 3 d. All animal experiments were approved by the Ethical Committee of the National Institute for Materials Science (NIMS), Japan. All animal experiments and feeding were carried out in accordance with the guidelines of the Ethical Committee of NIMS, Japan.

2 Results and discussion

AlOOH NSs with a tunable specific surface area and pore size were hydrothermally synthesized by using the inorganic aluminum salt AlCl3as Al source, urea as alkaline source and triblock copolymer P123 as templates. The hydrothermal products obtained at 100 ℃ for 6.5 and 24 h were named Al-L and Al-H, respectively.TEM images of Al-L and Al-H show the morphology of NSs with particle size of 10–30 nm (Fig. 1(A)).AFM image of Al-H show the thickness of NSs around 2 nm (Fig. 1(B)).The nitrogen adsorption–desorption isotherms (Fig. 1(C)) of Al-L and Al-H show a capillary condensation step in the relative pressure ranges of 0.4–0.6 and 0.45–0.8, respectively. Fig. 1(C) inset shows that the mesopore sizes of Al-L and Al-H center at approximately 3 and 5 nm, respectively. The surface area and pore volume were calculated to be 287 m2/g and 0.24 cm3/g for Al-L, and 470 m2/g and 0.53 cm3/g for Al-H, respectively. Wide-angle X-ray diffraction patterns demonstrate the presence of broadening reflection peaks (020), (120) and (031), which corresponds to the formation of the-AlOOH phase (boehmite) with a low crystallinity(Fig. 1(D)).Importantly, the obtained Al-H samples exhibited an extremely high specific surface area compared with those in previous reports[15-18]. For instance, γ-AlOOH hollow microspheres prepared by a hydrothermal precipitation reaction of potassium aluminum sulfate in the presence of urea in pure water yield a BET surface area of 93.6 m2/g[15]. In another case, nanostructured boehmite synthesizeda solvothermal route using aluminum nitrate and an isopropanol–toluene mixture as solvent shows a specific surface area of ca. 264.7 m2/g[16]. In addition, curtain-like crumpled boehmite prepared by using aluminum sulfate and hexamethylenetetramine displays a specific surface area of 353 m2/g, whereas theoretical calculation demonstrates that one-lattice boehmite sheets possess a surface area of 529 m2/g[18]. Although mesoporous boehmite by the hydrolysis reaction of aluminum-butoxide in an ethanol–water solution with an amine surfactant reportedly possesses a high surface area of 462 m2/g, the utilization of expensive and toxic aluminum organic reagents did not facilitate its biomedical application[19]. In the present study, we use the cheap aluminum inorganic salt AlCl3as aluminum source to obtain aluminum hydroxide with a high specific surface area and prevent the use of expensive and toxic aluminum organic reagents.

The structure-dependent chemotherapy drug loading capability and release behavior of the AlOOH NSs were verified by using the chemotherapy drugs Dox (Fig. 1(E)). The Al-H sample with a high surface area and large pore size showed about two times higher Dox loading ability compared with the Al-L sample with a low surface area and small pore size. The loading efficiency of Dox onto Al-L and Al-H is 14% and 31%, respectively.The surface area-dependent drug loading ability of the AlOOH NSs was also observed in a previous mesoporous silica delivery system loaded with the anti-inflammation drug ibuprofen[20]. The storage capacity of nanocarriers highly depends on the specific surface area and pore volume of the mesoporous carrier; a larger specific surface area and pore volume leads to a higher storage capacity[20].Notably, the AlOOH NSs loaded with Dox showed a pH-dependent sustained release behavior with a high release at a low pH of approximate 5 but a low release at a pH of around 7.4. For example, the Al-H/Dox samples exhibited a high release of (46.4%±3.5%) at day 1 and (99%± 14%) at day 12 at a low pH of 5 but a low release of (12.1%± 0.9%) at day 1 and (42.7%±4.3%) at day 12 at pH 7.4.

Fig. 1 (A) Transmission electron micrograph images of Al-L (a) and Al-H (b, c); (B) Atomic force microscopy image of Al-H; (C) N2 sorption isotherms and pore size distribution curves of the samples; (D) XRD patterns of the samples; (E) The release curves of Dox for the AlOOH NSs

The zeta potentials of the AlOOH NSs before and after Dox loading were recorded to analyze the interaction between particles and Dox molecules. The zeta potential increased from ?21.29 mV to ?7.23 mV after Dox loading onto the Al-H sample because of the positive charge of Dox with amine group. Meanwhile, the zeta potential changed from ?24.71 mV to ?16.90 mV after Dox loading onto the Al-L sample particles. The similar zeta potential for the initial Al-H and Al-L samples and the larger zeta potential change for the Al-H samples after Dox loading are consistent with the higher Dox loading amount. In addition, the AlOOH NSs displayed the following pH-dependent zeta potentials: 23.21 mV at pH 5, ?17.15 mV at pH 7.4, and ?21.29 mV at pH 8. The negative charge at a high pH of around 8.0 resulted in the electrostatic attraction between the AlOOH NSs and Dox molecules, whereas the positive charge at a low pH of around 5.0 led to electrostatic repulsion between each other and the release of loaded Dox molecules.

The cellular uptake of the Al-H/Dox samples was observed under a confocal laser scanning microscope. Fluorescein isothiocyanate (FITC)-conjugated Al-H samples were used to load Dox to form FITC-Al-H/Dox complexes. The obtained complexes were incubated with DU145 cells for different times and then observed. As shown in Fig. 2(A), green fluorescence emitted by FITC-Al-H was visualized in cells and primarily distributed near the cell membrane. This result suggests that the particles loaded with Dox were endocytosed by DU145 cells and internalized into the cells. The internalized amounts of FITC-Al-H/Dox samples in the cytoplasm and the Dox amount in the nucleus evidently increased with prolonged time from 0.5 h to 24 h.

The quantitative calculation of the cellular uptake of the Al-L/Dox, Al-H/Dox, and free Dox samples was conducted using flow cytometry based on the red fluorescence of Dox (Fig. 2(B, C)). At 5 μg/mL of the initial AlOOH NS particles, the Al-H/Dox samples exhibited a considerably higher cellular uptake percentage of 86.59% compared with the Al-L/Dox samples (26.92%) because of the higher Dox loading ability of the Al-H samples. Although both Al-L/Dox and Al-H/Dox samples showed almost 100% of cellular uptake at higher particle concentration, the peak fluorescence intensity evidently shifted to the right side for the Al-H/Dox samples (data not shown). Moreover, the cellular uptake percentages of DU145 cells for Al-H/Dox and free Dox were 86.59% and 41.51%, respectively, when the Dox amount was normalized to that loaded onto 5 μg/mL of Al-H particles. Similarly, at higher concentration, the fluorescence intensity of Al-H/Dox was considerably higher than that of free Dox, regardless of their 99.24% and 97.22% cellular uptake percentages, respectively (data not shown).

Fig. 2 (A) Confocal laser scanning micrographs of cellular uptake of Al-H/Dox samples by DU145 cells after coculture for 0.5 (a), 2.5 (b) and 24 h (c); (B) Histogram and (C) quantitative results of Dox cellular uptake efficiency (E%) by DU145 cells incubated for 2 h with (a) control, (b) Al-L/Dox at 5 μg/mL of particles, (c) Al-H/Dox at 5 μg/mL of particles, and (d) free Dox with an equivalent amount of Dox loaded onto Al-H/Dox samples

Fig. 3 Percentage of apoptosis and necrosis in DU145 cells treated with control (A), Al-L/Dox at 25 μg/mL (B), or Al-H/Dox at 25 μg/mL (C) for 1 d; Free Dox with an equivalent amount of Dox released from Al-H/Dox after 1 d at pH 5 was used as contrast (D)

The ratios of normal, early apoptosis, late apoptosis, and necrosis in DU145 cells treated with Al-L/Dox, Al-H/Dox and free Dox samples (Fig. 3) were studied using double staining with Annexin V-FITC and propidium iodide (PI). The group without any treatment was used as control. Normal live cells were considered to be double negative. Early apoptosis represents cells with Annexin V-FITC positive and PI negative staining. Late apoptosis means double positive cells. Necrosis cells were positive for PI and negative for Annexin V-FITC. Both Al-L/Dox and Al-H/Dox samples showed particle- concentration-dependent cell death. In total, the Al-H/Dox samples displayed substantially higher ratios of cellular death compared with the Al-L/Dox samples. This result is consistent with the Dox loading amount and cellular uptake efficiency. For example, the Al-L/Dox samples exhibited a ratio of 3.38% in early apoptosis, 6.17% in late apoptosis, and 5.64% in necrosis at 25 μg/mL. While, the percentages of late apoptosis and necrosis for the Al-H/Dox samples at 25 μg/mL increased to 22.68% and 44.37%, respectively, and the percentage of normal cells decreased to 31.73%. In addition, on the basis of the equivalent amount of Dox released from Al-H/Dox after 1 d at pH 5, the Al-H/Dox samples exhibited higher ratios of late apoptosis and necrosis compared with free Dox.

Fig. 4 Blood biochemistry analysis (A?E) of mice after intravenous administration with Al-H (n=3)

toxicology was carried outintravenous injection of Al-H into C57/BL6 mice (Fig. 4). Then, various kinds of biochemistry parameters, such as blood urea nitrogen (BUN), creatinine (CRE), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), were tested. The levels of liver function markers (, ALT, AST, and ALP) and kidney function markers (, CRE and BUN) were within the normal range compared with the control. No obvious hepatic or renal toxicity was observed after the intravenous injection of Al-H.

The AlOOH NSs with a high surface area reduce the side effects of chemotherapy drugs and overcome the influence of MDR. First, the pH-dependent release for Dox-loaded AlOOH NSs is meaningful in decreasing the side effects of chemotherapy drugs, considering that Dox suffers from the dose-dependent side effect of cardiotoxicity[1].Tumor sites are weakly acidic (~5.8) compared with the relatively high pH (~7.4) in blood or extracellular fluid in normal tissue[21]. This condition facilitates the passive targeting of chemotherapy drugs to tumor sites and decreases injury on normal cells based on enhanced permeability and retention effects[4]. Moreover, Dox loading onto AlOOH NSs helps overcome MDR, which excludes drug molecules outside the cancer cells owing to the overexpression of certain transporter proteins. The loading of Dox onto AlOOH NSs apparently increased the cellular uptake efficiency of drug molecules compared with that in free form, given that free Dox enters cancer cells through diffusion and Dox-loaded AlOOH NSs are internalized through endocytosis process[22-23]. In general, the cellular uptake efficiency through endocytosis is markedly higher than that through diffusion[22-23]. The Dox-loaded AlOOH NS particles endocytosed by cancer cells are first located in endosomes with a pH of around 6 and then fuse with lysosomes at pH ~5[24-25]; the condition results in the gradual release of Dox from the carrier.

AlOOH NSs are promising inorganic carriers with the lowest barrier for clinical transfer. These inorganic components have been used as vaccine adjuvants for humans since the 1920s because of their excellent biocompatibility and safety record as clinically confirmed by medical doctors. In 1926, alum was discovered as an adjuvant in a tetanus toxin vaccine. Although the detailed mechanism for alum as a human vaccine remains controversial and unclear, the synthesis of well-controlled AlOOH NSs may facilitate a better understanding of the alum delivery system and broaden its biomedical applications.

3 Conclusions

In summary, AlOOH NSs with a tunable pore size and surface area were prepared and used to load chemotherapy drug Dox.AlOOH NSs with high surface area and pore size delivered higher amount of chemotherapy drugs than those with low surface area and pore size. A pH-dependent sustained release behavior was observed for Dox-loaded AlOOH NSs with high release at a low pH of around 5 and low release at pH ~7.4. The Dox-loaded AlOOH NSs exhibited a markedly higher cancer cellular uptake efficiency compared with free-formDox. Moreover, the Dox-loaded AlOOH NSs with high specific surface area exhibited higher cellular uptake efficiency, apoptosis and necrosis ratios compared with those with a low specific surface area. This study paves the way for the exploration of AlOOH NSs with adjustable nanostructures as promising chemotherapy drug delivery system.

[1] SINGAL P, LI T M, KUMAR D,. Adriamycin-induced heart failure: mechanisms and modulation., 2000, 207: 77–86.

[2] GILLET J P, GOTTESMAN M M. Mechanisms of multidrug resistance in cancer., 2010, 596: 47–76.

[3] PERSIDIS A. Cancer multidrug resistance.., 1999, 17: 94–95.

[4] PEER D, KARP J M, HONG S,. Nanocarriers as an emerging platform for cancer therapy.., 2007, 2(12): 751–760.

[5] MALTZAHM G V, PARK J H, LIN K Y,. Nanoparticles that communicateto amplify tumour targeting.., 2011, 10: 545–552.

[6] ASHLEY C E, CARNES E C, PHILLIPS G K,. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers.., 2011, 10: 389–397.

[7] CHEN Y, TAN C, ZHANG H,Two-dimensional graphene analogues for biomedical applications.., 2015, 44: 2681–2701.

[8] CHIMENE D, ALGE D L, GAHARWAR A K. Two-dimensional nanomaterials for biomedical applications: emerging trends and future prospects., 2015, 27: 7261–7284.

[9] WU J, ZHU Y J, CHEN F. Ultrathin calcium silicate hydrate nanosheets with large specific surface areas: synthesis, crystallization, layered self-assembly and applications as excellent adsorbents for drug, protein, and metal ions., 2013, 9: 2911–2925.

[10] EISENBARTH S C, COLEGIO O R, JR W O C,. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants., 2008, 453(7198): 1122–1126.

[11] FLACH T L, NG G, HARI A,. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity., 2011, 17: 479–487.

[12] MARICHAL T, OHATA K, BEDORET D,. DNA released from dying host cells mediates aluminum adjuvant activity., 2011, 17: 996–1002.

[13] LI X, WANG X P, ITO A. Tailoring inorganic nanoadjuvants towards next-generation vaccines., 2018, 47: 4954–4980.

[14] SUN B, JI Z, LIAO Y P,Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles., 2013, 7: 10834–10849.

[15] CAI W, YU J, MANN S. Template-free hydrothermal fabrication of hierarchically organized-AlOOH hollow microspheres., 2009, 122: 42–47.

[16] LI G, GUAN L, LIU Y,Template-free solvothermal synthesis of 3D hierarchical nanostructured boehmite assembled by nanosheets., 2012, 73: 1055–1060.

[17] WANG X P, LI X, SOGO Y,Simple synthesis route of mesoporous AlOOH nanofibers to enhance immune responses., 2013, 3: 8164–8167.

[18] WEN J R, LIU M H, MOU C Y. Synthesis of curtain-like crumpled boehmite and-alumina nanosheets., 2015, 17: 1959–1967.

[19] HICKS R W, PINNAVAIA T J. Nanoparticle assembly of mesoporous AlOOH (Boehmite)., 2003, 15: 78–82.

[20] LI X, WANG X, HUA Z,. One-pot synthesis of magnetic and mesoporous bioactive glass composites and their sustained drug release property.., 2008, 56: 3260–3265.

[21] BARRETO J A, O’MALLEY W, KUBEIL M,. Nanomaterials: applications in cancer imaging and therapy.., 2011, 23: H18–H40.

[22] BILDSTEIN L, DUBERNET C, COUVREUR P. Prodrug-based intracellular delivery of anticancer agents.., 2011, 63: 3–23.

[23] SKOVSGAARD T, NISSEN N I. Membrane transport of anthracyclines., 1982, 18: 293–311.

[24] LI X, WANG X, SOGO Y,. Mesoporous silica-calcium phosphate- tuberculin purified protein derivative composites as an effective adjuvant for cancer immunotherapy.., 2013, 2: 863–871.

[25] BLOEBAUM R D, LUNDEEN G A, BACHUS K N,. Dissolution of particulate hydroxyapaptite in a macrophage organelle model.., 1998, 40: 104–114.

氫氧化鋁納米片: 結(jié)構(gòu)依賴性癌癥化療藥物的儲運

LI Xia1, SHENASHEN Mohamed A1, MEKAWY Moataz1,TANIGUCHI Akiyoshi2,3, EI-SAFTY Sherif A1,3

(1. Research Center for Functional Materials, National Institute for Materials Science, Ibaraki 305-0047, Japan; 2. Cellular Functional Nanomaterials Group, Research Center for Functional Materials, National Institute for Materials Science, Tsukuba, Ibaraki 305-0044, Japan; 3. Engineering and Advanced Manufacturing, University of Sunderland, Sunderland, United Kingdom)

鋁鹽佐劑具有極好的安全記錄, 是各種人類疫苗中唯一獲得FDA許可的無機佐劑。據(jù)我們所知, 目前尚沒有關(guān)于將其用作化療藥物的遞送系統(tǒng)、并系統(tǒng)闡明其結(jié)構(gòu)與載藥性能之間關(guān)系的研究報道。本研究采用三嵌段共聚物、通過調(diào)節(jié)反應時間合成了具有可調(diào)比表面積和孔徑的氫氧化鋁(AlOOH)納米片。AlOOH 納米片的最大比表面積達470 m2/g。其負載化療藥物阿霉素的能力與材料結(jié)構(gòu)密切相關(guān): 比表面積和孔徑越大, 負載化療藥物的量越大。負載有阿霉素的AlOOH 納米片呈現(xiàn)與pH有關(guān)的藥物釋放行為: 在pH~5的低pH 環(huán)境下快速釋放, 而在pH~7.4 的近中性pH 下緩慢釋放。流式細胞術(shù)顯示, 相比于游離形式的阿霉素, 負載在AlOOH 納米片上的阿霉素更易被癌細胞所吞噬。而且負載阿霉素后, 與低比表面積的AlOOH納米片相比, 高比表面積的AlOOH 納米片更有利于被癌細胞攝取、誘導癌細胞凋亡和壞死。因此, 本研究所合成的AlOOH 納米片有望用作化療藥物遞送體系。

氫氧化鋁; 納米片; 癌癥化療; 存儲; 藥物輸送

TQ174

A

2019-01-25;

2019-08-06

National Institute for Materials Science of Japan

LI Xia (1980-), female, PhD. E-mail: lixia6969@hotmail.com

李霞(1980-), 女, 博士. E-mail: lixia6969@hotmail.com

EI-SAFTY Sherif A. E-mail: Sherif.ELSAFETY@nims.go.jp

1000-324X(2020)02-0250-07

10.15541/jim20190052